TY  - JOUR
AU  - Joksić, Gordana
AU  - Rutqvist, Lars Erik
AU  - Mićić, Mileva
AU  - Filipović Tričković, Jelena G.
AU  - Nilsson, Robert
PY  - 2019
UR  - https://linkinghub.elsevier.com/retrieve/pii/S0273230019300601
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8080
AB  - Long term exposure to oral smokeless tobacco may induce lesions in the oral cavity characterized by a hyperplastic epithelium. The possible role of nicotine and the physical properties of oral tobacco for developing these lesions, as well as of dysplasia and neoplasia is unclear. Low nitrosamine Swedish snus as well as non-genotoxic butylated hydroxyanisole induces increased cellular proliferation in the rat forestomach epithelia. Using this model, we report here on the effects of nicotine, pH, and particle size. Snus with different properties had no impact on oxidative stress as determined by 8-oxo-7,8-dihydro-2′-deoxyguanosine, or on interleukin IL-1b. Whereas BHA boosted IL-6, probably due to the presence of nicotine. there was no significant enhancement of cell divisions with increasing particle size, although in individual samples the variations in proliferation rates increased greatly with increasing particle size. Conforming to human experience, the enhanced cell proliferation caused by snus was found to be completely reversible. A cacao bean extract had a protective action similar to that previously found for blueberries. The main cause of the observed tobacco induced cell proliferation could be mechanical irritation, possibly in combination with nicotine, whereas within the studied range, pH did not affect the rate of cell division. © 2019
T2  - Regulatory Toxicology and Pharmacology
T1  - Factors effecting the induction of rat forestomach hyperplasia induced by Swedish oral smokeless tobacco (snus)
VL  - 104
SP  - 21
EP  - 28
DO  - 10.1016/j.yrtph.2019.02.015
ER  - 

@article{
author = "Joksić, Gordana and Rutqvist, Lars Erik and Mićić, Mileva and Filipović Tričković, Jelena G. and Nilsson, Robert",
year = "2019",
abstract = "Long term exposure to oral smokeless tobacco may induce lesions in the oral cavity characterized by a hyperplastic epithelium. The possible role of nicotine and the physical properties of oral tobacco for developing these lesions, as well as of dysplasia and neoplasia is unclear. Low nitrosamine Swedish snus as well as non-genotoxic butylated hydroxyanisole induces increased cellular proliferation in the rat forestomach epithelia. Using this model, we report here on the effects of nicotine, pH, and particle size. Snus with different properties had no impact on oxidative stress as determined by 8-oxo-7,8-dihydro-2′-deoxyguanosine, or on interleukin IL-1b. Whereas BHA boosted IL-6, probably due to the presence of nicotine. there was no significant enhancement of cell divisions with increasing particle size, although in individual samples the variations in proliferation rates increased greatly with increasing particle size. Conforming to human experience, the enhanced cell proliferation caused by snus was found to be completely reversible. A cacao bean extract had a protective action similar to that previously found for blueberries. The main cause of the observed tobacco induced cell proliferation could be mechanical irritation, possibly in combination with nicotine, whereas within the studied range, pH did not affect the rate of cell division. © 2019",
journal = "Regulatory Toxicology and Pharmacology",
title = "Factors effecting the induction of rat forestomach hyperplasia induced by Swedish oral smokeless tobacco (snus)",
volume = "104",
pages = "21-28",
doi = "10.1016/j.yrtph.2019.02.015"
}

Joksić, G., Rutqvist, L. E., Mićić, M., Filipović Tričković, J. G.,& Nilsson, R.. (2019). Factors effecting the induction of rat forestomach hyperplasia induced by Swedish oral smokeless tobacco (snus). in Regulatory Toxicology and Pharmacology, 104, 21-28.
https://doi.org/10.1016/j.yrtph.2019.02.015

Joksić G, Rutqvist LE, Mićić M, Filipović Tričković JG, Nilsson R. Factors effecting the induction of rat forestomach hyperplasia induced by Swedish oral smokeless tobacco (snus). in Regulatory Toxicology and Pharmacology. 2019;104:21-28.
doi:10.1016/j.yrtph.2019.02.015 .

Joksić, Gordana, Rutqvist, Lars Erik, Mićić, Mileva, Filipović Tričković, Jelena G., Nilsson, Robert, "Factors effecting the induction of rat forestomach hyperplasia induced by Swedish oral smokeless tobacco (snus)" in Regulatory Toxicology and Pharmacology, 104 (2019):21-28,
https://doi.org/10.1016/j.yrtph.2019.02.015 . .

TY  - JOUR
AU  - Joksić, Gordana
AU  - Spasojević-Tišma, Vera D.
AU  - Antic, Ruza
AU  - Nilsson, Robert
AU  - Rutqvist, Lars Erik
PY  - 2011
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/4346
AB  - Background: Epidemiological studies suggest that smokeless tobacco in the form of Swedish snus has been used by many smokers in Scandinavia to quit smoking, but the efficacy of snus has so far not been evaluated in controlled clinical trials. Methods: We conducted a randomized, double-blind, placebo-controlled, clinical trial aimed at assessing the efficacy of snus to help adult cigarette smokers in Serbia to substantially reduce, and, eventually, completely stop smoking. The study enrolled 319 healthy smokers aged 20-65 years at two occupational health centers in Belgrade, Serbia. Most of them (81%) expressed an interest to quit rather than just reduce their smoking. Study products were used ad libitum throughout the 48-week study period. The main study objective during the first 24 weeks was smoking reduction. The primary end-point was defined as a biologically verified reduction of GT = 50% in the average number of smoked cigarettes per day during week 21-24 compared to baseline. During week 25-48 participants were actively instructed to stop smoking completely. Outcome measures of biologically verified, complete smoking cessation included 1-week point prevalence rates at clinical visits after 12, 24, 36, and 48 weeks, as well as 4-, 12- and 24-week continued cessation rates at the week 36 and 48 visits. Results: At the week 24 visit, the proportion of participants who achieved the protocol definition of a GT = 50% smoking reduction was similar in the two treatment groups. However, the proportion that reported more extreme reductions ( GT = 75%) was statistically significantly higher in the snus group than in the placebo group (p LT 0.01). The results for biologically verified complete cessation suggested that participants in the snus group were more likely to quit smoking completely than the controls; the odds ratio (snus versus placebo) for the protocol estimates of cessation varied between 1.9 to 3.4, but these ratios were of borderline significance with p-values ranging from 0.04-0.10. Snus was well tolerated and only 2/158 (1.3%) participants in the snus group discontinued treatment due to an adverse event (in both cases unrelated to snus). Conclusions: Swedish snus could promote smoking cessation among smokers in Serbia, that is, in a cultural setting without traditional use of oral, smokeless tobacco.
T2  - Harm Reduction Journal
T1  - Randomized, placebo-controlled, double-blind trial of Swedish snus for smoking reduction and cessation
VL  - 8
DO  - 10.1186/1477-7517-8-25
ER  - 

@article{
author = "Joksić, Gordana and Spasojević-Tišma, Vera D. and Antic, Ruza and Nilsson, Robert and Rutqvist, Lars Erik",
year = "2011",
abstract = "Background: Epidemiological studies suggest that smokeless tobacco in the form of Swedish snus has been used by many smokers in Scandinavia to quit smoking, but the efficacy of snus has so far not been evaluated in controlled clinical trials. Methods: We conducted a randomized, double-blind, placebo-controlled, clinical trial aimed at assessing the efficacy of snus to help adult cigarette smokers in Serbia to substantially reduce, and, eventually, completely stop smoking. The study enrolled 319 healthy smokers aged 20-65 years at two occupational health centers in Belgrade, Serbia. Most of them (81%) expressed an interest to quit rather than just reduce their smoking. Study products were used ad libitum throughout the 48-week study period. The main study objective during the first 24 weeks was smoking reduction. The primary end-point was defined as a biologically verified reduction of GT = 50% in the average number of smoked cigarettes per day during week 21-24 compared to baseline. During week 25-48 participants were actively instructed to stop smoking completely. Outcome measures of biologically verified, complete smoking cessation included 1-week point prevalence rates at clinical visits after 12, 24, 36, and 48 weeks, as well as 4-, 12- and 24-week continued cessation rates at the week 36 and 48 visits. Results: At the week 24 visit, the proportion of participants who achieved the protocol definition of a GT = 50% smoking reduction was similar in the two treatment groups. However, the proportion that reported more extreme reductions ( GT = 75%) was statistically significantly higher in the snus group than in the placebo group (p LT 0.01). The results for biologically verified complete cessation suggested that participants in the snus group were more likely to quit smoking completely than the controls; the odds ratio (snus versus placebo) for the protocol estimates of cessation varied between 1.9 to 3.4, but these ratios were of borderline significance with p-values ranging from 0.04-0.10. Snus was well tolerated and only 2/158 (1.3%) participants in the snus group discontinued treatment due to an adverse event (in both cases unrelated to snus). Conclusions: Swedish snus could promote smoking cessation among smokers in Serbia, that is, in a cultural setting without traditional use of oral, smokeless tobacco.",
journal = "Harm Reduction Journal",
title = "Randomized, placebo-controlled, double-blind trial of Swedish snus for smoking reduction and cessation",
volume = "8",
doi = "10.1186/1477-7517-8-25"
}

Joksić, G., Spasojević-Tišma, V. D., Antic, R., Nilsson, R.,& Rutqvist, L. E.. (2011). Randomized, placebo-controlled, double-blind trial of Swedish snus for smoking reduction and cessation. in Harm Reduction Journal, 8.
https://doi.org/10.1186/1477-7517-8-25

Joksić G, Spasojević-Tišma VD, Antic R, Nilsson R, Rutqvist LE. Randomized, placebo-controlled, double-blind trial of Swedish snus for smoking reduction and cessation. in Harm Reduction Journal. 2011;8.
doi:10.1186/1477-7517-8-25 .

Joksić, Gordana, Spasojević-Tišma, Vera D., Antic, Ruza, Nilsson, Robert, Rutqvist, Lars Erik, "Randomized, placebo-controlled, double-blind trial of Swedish snus for smoking reduction and cessation" in Harm Reduction Journal, 8 (2011),
https://doi.org/10.1186/1477-7517-8-25 . .